Serendipity Discovers the Holy Grail of Regenerative Cardiology releases a breakthrough research report that solves regenerative cardiology companies’ unyielding problem of translating positive pre-clinical data into successful human trials.

St Leonards on Sea, United Kingdom, September 17, 2008 --( “In the 70 year history of FDA 11,808 new drug applications were approved and 1,427 new molecular entities introduced in the healthcare market. It’s the rigors of the regulatory process of developing new drugs that pushed the industry and academia to evolve clinical pharmacology to an incomprehensible credulity that it enjoys today. Each one of an estimated 120,000 potential drugs that entered the clinical phase of the regulatory approval process in those 70 years ardently obeyed the laws of pharmacokinetics (PK) and pharamcodynamics (PD). But one clinical situation changed all of that. One therapeutic approach defied all efforts to translate the positive animal data to successful clinical trials. One indication defeated all the time tested principles of PK/PD Modeling and eluded success. Yet, that indication remains in hot pursuit - Regenerative Cardiology.”

Those words from a new research report released by entitled “Neocardiogenesis – Celebrating The Birth Of Regenerative Cardiology,” may sound quite perplexing to those committed to treating sick hearts by exploiting heart’s own self-renewing qualities, but they reveal the uniqueness of Regenerative Cardiology that has marred the clinical trials.

Regenerating the damaged human heart therapeutically is the new paradigm that was a heresy not too long ago. With over 80 companies in active pursuit, a lot more in academia, and umpteen unregulated but thriving “magic cure” centers worldwide, the development of a therapy for mending broken hearts is indeed Gold Rush of the 21st century.

“We know of no single clinical indication in the history that has received so much funding and attention, and yet eluding success for almost a decade.” Says Fazal Raheman MD, CEO of MRI Limited, the British firm that conducted the research. “Initiated purely as a market research project for providing business intelligence to biotechnology companies, this research became what it was never intended to – A Treatise of Inventions ,” explains Dr Raheman.

The release of this report was especially delayed for filing first of the three patents that resulted from the research. Dr Raheman comments, “many inventions and discoveries have been made in serendipity, but none to our knowledge happened while working on a market analysis project. We saw a problem. We could visualize the solution; and there it was - a new approach that could potentially end the efficacy stalemate.”

The report provides breakthrough analyses and conclusions that are completely original, unprecedented, and have the potential to guide any protein, gene or cell based therapy to the path of success. The report also covers over 80 companies in this field. A free preview of all the 17 Sections of the report is available at

About is a wholly owned division of MRI Limited, a British Corporation, a technology development and consulting outfit with expertise widely ranging from inventing new therapeutics and disease management approaches to developing intangible life sciences and technology knowledge assets into commercially quantifiable intellectual properties. MRI conducts contract research for clients as well as in-house research for developing its own portfolio of intellectual properties.

Forward Looking Statements
Any statements in this release that are not historical facts may be considered forward-looking statements, including statements regarding the contents of the new research report on regenerative cardiology. Undue reliance should not be placed on forward-looking statements, which speak only as of the time they are made and subjected to uncertainties and contingencies, many of which are beyond the control of the Company. or MRI undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, changed assumptions or otherwise. Actual results or experience could differ materially from the forward-looking statements.

MRI Limited
Dr Fazal Raheman